LDL-CHOLESTEROL REDUCTION WITH PCSK9 INHIBITORS: A META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

被引：2
|
作者：
Casula, Manuela [1 ]
Scotti, Lorenza [2 ]
Bernocchi, Ottavia [1 ]
Galimberti, Federica [1 ]
Tragni, Elena [1 ]
Corrao, Giovanni [2 ]
Catapano, Alberico Luigi [1 ,3 ]
机构：
[1] Univ Milan, Epidemiol & Prevent Pharmacol Ctr SEFAP, Milan, Italy
[2] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Milan, Italy
[3] IRCCS MultiMed, Sesto San Giovanni, MI, Italy
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.789
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO436
引用
收藏
页码：E244 / E244
页数：1
相关论文
共 50 条
  • [1] Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials
    Casula, Manuela
    Olmastroni, Elena
    Boccalari, Mezio T.
    Tragni, Elena
    Pirillo, Angela
    Catapano, Alberico L.
    [J]. PHARMACOLOGICAL RESEARCH, 2019, 143 : 143 - 150
  • [2] LDL-cholesterol targets: perspectives for the use of PCSK9 inhibitors
    Luscher, Thomas F.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1337 - 1340
  • [3] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
  • [4] PCSK9 Inhibitors The Magic Bullet for LDL Cholesterol Reduction?
    Richter, Kurt
    Barthel, Andreas
    Bornstein, Stefan R.
    El-Armouche, Ali
    Wagner, Michael
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 863 - U181
  • [5] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    [J]. ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [6] Cholesterol reduction with PCSK9 inhibitors
    Lambooij A.
    [J]. Huisarts en wetenschap, 2018, 61 (9) : 18 - 20
  • [7] Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
    Dicembrini, I.
    Giannini, S.
    Ragghianti, B.
    Mannucci, E.
    Monami, M.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (09) : 1029 - 1039
  • [8] Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
    I. Dicembrini
    S. Giannini
    B. Ragghianti
    E. Mannucci
    M. Monami
    [J]. Journal of Endocrinological Investigation, 2019, 42 : 1029 - 1039
  • [9] PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
    Luo, Jichang
    Liao, Wanying
    Wang, Xue
    Xu, Ran
    Li, Wei
    Li, Wenjing
    Liu, Kan
    Huang, Kaixun
    Ma, Yan
    Wang, Tao
    Yang, Bin
    Jiao, Liqun
    [J]. BMJ OPEN, 2022, 12 (11):
  • [10] PCSK9 MUTATIONS AND LDL-CHOLESTEROL IN THE BOGALUSA HEART STUDY
    Hallman, D. M.
    Srinivasan, S.
    Chen, W.
    Boerwinkle, E.
    Berenson, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
12345